BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24166914)

  • 1. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
    Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
    Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant colon cancer chemotherapy: where we are and where we'll go.
    Lombardi L; Morelli F; Cinieri S; Santini D; Silvestris N; Fazio N; Orlando L; Tonini G; Colucci G; Maiello E
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S34-41. PubMed ID: 21129608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
    Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
    Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
    Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
    Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current issues in adjuvant treatment of stage II colon cancer.
    André T; Sargent D; Tabernero J; O'Connell M; Buyse M; Sobrero A; Misset JL; Boni C; de Gramont A
    Ann Surg Oncol; 2006 Jun; 13(6):887-98. PubMed ID: 16614880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline.
    Jonker DJ; Spithoff K; Maroun J;
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):314-22. PubMed ID: 21397476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common cancer stem cell gene variants predict colon cancer recurrence.
    Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
    Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
    Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
    Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.